Meeting
2021 ASCO Annual Meeting
Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL).
Presenter
Wojciech Jurczak, MD, PhD
National Research Institute of Oncology
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04745832
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7573)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7573
Abstract #
TPS7573
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: David N. Hayes, MD, MPH
Videos & Slides
2024 ASCO Annual Meeting
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Speaker: Jurriaan Brouwer, PhD
Videos & Slides
2023 ASCO Annual Meeting
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Speaker: Jason Westin, MD, FACP, MS
Videos & Slides
2023 ASCO Annual Meeting
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
Speaker: Loretta J. Nastoupil, MD